Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarinâ€™s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarinâ€™s cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. Amarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN)
Current Team (4)Update
Board Members and Advisors (5)Update
Fountain Healthcare Partners is an Irish-based life science venture capital fund. Fountain is...
First Floor, Block 3, The Oval,
Shelbourne Road, Dublin 4,